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Myotonic dystrophy type 1 (DM1) is caused by the 
expansion of (CTG)n in the 3′ untranslated region of 
the dystrophia myotonica-protein kinase (DMPK) gene, 
which is transcribed as (CUG)n repeats that accumulate 
in the nucleus. The RNA repeats specifically sequester or 
change the expression levels of several RNA-binding pro-
teins, leading to aberrant splicing of many target genes. 
In this study, we developed artificial site-specific RNA 
endonucleases (ASREs) that specifically bind and cleave 
(CUG)n repeats RNA. We have generated one ASRE that 
can target the expanded RNA repeats in DM1 patient 
cells and specifically degrade the pathogenic DMPK mes-
senger RNAs with minimal effect on wild-type alleles. 
Such ASRE treatment significantly decreased the num-
ber of nuclear foci in DM1 patient cells and can reverse 
the missplicing of many genes affected in DM1 patients. 
Taken together, the application of ASRE provides a new 
route of gene therapy for DM1 treatment.
Received 7 June 2013; accepted 17 October 2013; advance online  
publication 10 December 2013. doi:10.1038/mt.2013.251
INTRODUCTION
Myotonic dystrophy type 1 (DM1), the most common form of 
adult muscular dystrophy with a prevalence of ~1:8,000 world-
wide, is an autosomal dominant disease with multisystemic symp-
toms, including myotonia, muscle wasting, cardiac conduction 
defects, insulin resistance, cataracts, and cognitive dysfunction 
(reviewed in ref. 1). DM1 is caused by the progressive expansion 
of (CTG) triplet in the 3′ untranslated region of dystrophia myo-
tonica-protein kinase (DMPK) gene on chromosome 19q13.3.2,3 
According to the prevailing model of DM1 pathogenesis, the 
triplet expansion is transcribed as toxic (CUG)n repeats RNA 
that accumulate in the nucleus as RNA–protein complex, which 
changes the levels of several RNA-binding proteins, including 
some important splicing factors.4,5
Two classes of splicing factors are well known to be affected 
by (CUG)n repeats: the Muscleblind-like family (MBNL1-3)
6–8 
and CUG-BP, Elav-like family (CELF).9,10 The members of MBNL 
family (e.g., MBNL1) have a high affinity for (CUG)n repeats and 
thus are sequestered in the nuclear foci, leading to a functional 
deficiency of these proteins.6–8 The levels of CELF proteins (e.g., 
CUGBP1) are upregulated in DM1 through a PKC-mediated 
phosphorylation event that stabilizes the protein.9,10 It was 
recently reported that a double-stranded RNA-binding protein, 
staufen1, is also increased in DM1 skeletal muscle and contrib-
utes to the splicing changes in DM1 cells.11 The changes of these 
splicing regulators interfere with the alternative splicing of hun-
dreds of genes,12 including insulin receptor (IR),13 cardiac tropo-
nin T (cTNT),9,14 bridging integrator-1 (BIN1),15 sarcoplasmic/
endoplasmic reticulum Ca2+-ATPase 1 (SERCA1)16,17, and more. 
Generally, the aberrant splicing caused the expression of embry-
onic isoforms in adult tissues of DM1 patients, resulting in symp-
toms that resemble developmental abnormality.18
Although some symptoms of DM1 can be alleviated, there is 
currently no cure for this disease. Specific therapy of DM1 is dif-
ficult because the toxic RNA repeats affect multiple factors that 
subsequently cause dysregulation of splicing in more than 100 pro-
teins.12 Several therapeutic approaches of DM1 are currently under 
investigation. The first is to restore the misregulated splicing fac-
tors with gene therapy approaches using adeno-associated virus 
(AAV) vectors.19 The strength of such protein-based approaches 
is the efficient delivery of protein to muscle and heart by available 
gene therapy vectors (such as AAV). However, because multiple 
splicing factors are affected either positively or negatively in DM1 
patients, conventional gene therapy approach cannot restore the 
normal level of all protein factors. The second strategy includes var-
ious antisense oligonucleotides–based methods to cleave (CUG)n 
repeats. This strategy has produced some promising results in cul-
tured cells20,21 and in animal models.21–24 However, the delivery of 
oligonucleotides in the muscle and heart of DM1 patients, together 
with the balance of delivery efficiency and toxicity, will be a major 
challenge. Another therapeutic route is to identify small molecules 
that inhibit the binding of (CUG)n to MBNL1.
25–28 Since these small 
molecules all bind to structured RNA repeats to release the MBNL1 
sequestered by (CUG)n, they are fairly toxic, and additional work is 
needed to increase their selectivity to specific RNA repeats.
Here, we report a novel therapeutic strategy that uses artificial 
site-specific RNA endonucleases (ASREs) containing a specific 
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an RNA endonuclease domain (PIN domain of human SMG6) 
to specifically bind and cleave (CUG)n repeats. We demonstrated 
that ASREs can decrease the levels of messenger RNA (mRNA) 
harboring long (CUG)n repeats and can significantly decrease the 
number of nuclear foci in DM1 patient cells. Expression of ASRE 
also reversed the missplicing of genes affected in DM1 patients. 
Taken together, this work represented a proof of principle for a 
new therapy that combines the strength of both protein- and oli-
gonucleotide-based approaches.
RESULTS
Generate the PUF domains that bind (CUG)n repeats
The ASREs were designed by combining the unique RNA recogni-
tion domain (PUF domain of human pumilio1) and a general RNA 
endonuclease domain (PIN domain of human SMG6).29 The PUF 
domain contains eight repeats that bind consecutive RNA bases in 
an antiparallel fashion. Each repeat uses two amino acids to recog-
nize the Watson–Crick edge of the corresponding base and a third 
amino acid (Tyr, His, or Arg) to stack between adjacent RNA bases, 
generating a specific binding between a PUF repeat and the cognate 
base.30,31 The PUF repeat in natural protein can recognize the bases 
A, U, and G in a modular fashion.30 In addition, we and another 
group recently identified the amino acid combination of PUF to 
specifically recognize cytosine using a yeast three-hybrid screen.32,33 
Completion of the unique RNA-binding code enabled us to repro-
gram the specificity of each PUF repeat to generate a designer 
domain that specifically recognizes any 8-nt RNA. The (CUG)n 
repeats contain three different RNA octamers (UGCUGCUG, 
GCUGCUGC, and CUGCUGCU) from different frames. Through 
stepwise mutagenesis on each PUF repeat, we generated three PUF 
domains, each recognizing one of the possible 8-nt in (CUG)n 
(Figure 1a; the first base of each sequence was used to name the 
PUF domain). Because the expanded (CUG)n repeats form a long 
hairpin in vitro based on the studies using electron microscopy and 
crystallography,34,35 the designer PUFs may recognize a series of 8-nt 
targets tandemly positioned along the hairpin structure (Figure 1b).
We used a yeast three-hybrid system to assay for the spe-
cific binding between the PUF domains with their cognate RNA 
targets. We cotransfected each PUF with a short RNA repeat 
(CUG)5, a long repeat (CUG)20, and a control repeat (CAG)20 into 
the YBZ-1 strains and assayed for the binding affinity between 
different PUF–RNA pairs as relative β-galactosidase activity.32,36 
The (CUG)5 contains one to two copies of the 8-nt targets in an 
unpaired conformation, whereas the (CUG)20 contains multiple 
8-nt targets and forms into a hairpin structure that resembles the 
toxic RNA in DM1 cells. We found that all PUFs can specifically 
bind (CUG)5 RNA with an affinity of ~2–10 fold of the wild-type 
(WT) PUF–RNA pair, suggesting that these PUFs indeed can 
recognize the target as designed. As controls, none of three PUFs 
bound to noncognate (CAG)20 RNA with similar structure, indi-
cating that the binding between the designer PUFs and the toxic 
(CUG)n repeat is specific. In addition, the binding affinity between 
(CUG)20 repeats and PUF(U) or PUF (C) is much higher (>15-
fold) than the binding between WT PUF and its target (sample 1 
in Figure 1c) as judged by LacZ activity.
However, PUF(U) and PUF(C), but not PUF(G), can bind 
to the long (CUG)20 repeats with high affinity. This observation 
suggested that the local structure of RNA target probably affects 
the recognition of RNA by PUF domain. PUF repeat recognizes 
its cognate RNA through direct contact of amino acids to the 
Watson–Crick edge of RNA bases.30–32 Therefore, this interaction 
is probably influenced by the accessibility of base: an RNA base 
in double-stranded RNA region is a poor PUF target because it is 
already paired with another base (i.e., the Watson–Crick edge is 
occupied), thus there may be a maximal number of paired bases 
that PUF can tolerate. The (CUG)n repeats form a hairpin struc-
ture in vitro with the U being unpaired,34 our results may suggest 
that the binding between PUF and RNA requires at least three 
unpaired nucleotides in the 8-nt target sequence (i.e., the maxi-
mal five paired–based can be tolerated; Figure 1b). In addition, 
there might be other possibilities, such as alternative structures 
of (CUG)n repeats or the binding of the repeats by other proteins 
or helicase, which are partially responsible for the difference 
observed.
The binding between PUFs and (CUG)n repeats RNA was 
further confirmed with electrophoretic mobility shift assay using 
the purified protein and in vitro transcribed (CUG)12 sequences. 
We found that PUF(U), but not PUF(G), can form stable complex 
with RNA repeats to cause the mobility shift of RNA (Figure 1d), 
consistent with the finding from yeast three-hybrid system 
(Figure 1c). The expression and purification of PUF(C) were 
attempted multiple times, but the protein was expressed poorly 
for unknown reason. This PUF(C) was expressed in extremely low 
level in both Escherichia coli and mammalian cells, thus we mainly 
used PUF(U) and PUF(G) for most of the remaining analyses.
Generation of ASREs to cleave (CUG)n repeats
To generate ASREs for (CUG)n repeats, we linked the designer 
PUF domains with the PIN domain using a short peptide linker. 
We also included a FLAG epitope tag for protein detection and a 
nuclear localization sequence (PKKKRKV) to facilitate the import 
of ARSEs into the nucleus where the (CUG)n repeats accumulate. 
The PIN domain of human SMG6 was chosen because it has a 
well-defined molecular architecture and requires only a divalent 
metal cation for RNA cleavage.37,38 As a control, we fused PUF(U) 
with an inactive PIN harboring a D1353A mutation in its active 
site.29,37 The resulting ASRE-(U), mutated ASRE-(U), ASRE-(G), 
and ASRE-(C) were used for further assays (Supplementary 
Figure S1).
To determine whether ASREs can degrade (CUG)n repeats 
RNA in cultured cells, we first tested the ASREs in COS7 cells 
transiently transfected with a plasmid reporter DT480 containing 
DMPK exon 11–15 and 480 interrupted CTG repeats in exon 15 
(Figure 2a).9,21 We found that ASRE-(U) caused >60% decrease 
in DT480 mRNAs by real-time reverse transcriptase–polymerase 
chain reaction (RT-PCR) and mutated ASRE-(U) with an inac-
tive PIN domain led to a small decrease, whereas the ASRE-(G) 
had little effects (Figure 2b). Because of extremely low expression 
level, ASRE-(C) had little effects on the level of DT480-containing 
mRNAs (not shown).
We also examined the effect of ASREs on the level of DMPK 
mRNAs containing normal number of (CUG)n repeats. We tran-
siently transfected COS7 cells with ASREs and the DT12 reporter 
that contains DMPK exon 11–15 with 12 interrupted CTG repeats 
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in exon 15 (Figure 2a). The real-time RT-PCR analysis showed 
that ASREs did not significantly affect the mRNA level of DT12, 
suggesting that the ASRE-catalyzed RNA degradation may be 
fairly slow and can only be observed with a large number of tar-
gets (Figure 2b).
Expression of ASREs degraded expanded (CUG)n 
repeats in DM1 cells
We further examined the cellular effect of designer ASREs on 
the (CUG)n repeats in DM1 patient cells. To convert fibroblasts 
into myoblasts, we transfected DM1 fibroblasts (GM04602 and 
GM04033), as well as a normal human foreskin fibroblast with 
a lentiviral vector encoding MyoD gene.39 The stably trans-
fected cells were further transfected with ASRE-(U), ASRE-(G), 
ASRE-(C), or a mutated ASRE-(U) with an inactive PIN domain, 
and the resulting myoblasts were induced into myocytes with 
differentiation medium containing horse serum, insulin, and 
transferrin (Figure 3a). After a 10-day differentiation period, we 
analyzed the expression of ASREs using western blot (Figure 3b) 
and immunofluorescence (Figure 3c) with anti-FLAG antibody. 
We found that ASRE-(U), ASRE-(G), and mutated ASRE-(U) 
were robustly expressed in ~70% of cells, whereas ARSE-(C) 
has very low level of expression in patient-derived myocytes. As 
expected, the ASREs were predominantly expressed in the nucleus 
(Figure 3c). In addition, the expression of ASRE-(U), but not the 
control ASRE-(G) or mutated ASRE-(U), reduced the endog-
enous DMPK mRNA level by 40% in DM1 cells (Figure 3d). If 
assuming that DMPK is transcribed equally from both WT and 
the CUG-expansion mutation alleles, we could roughly estimate 
that at least 80% of the mutated DMPK transcripts were degraded. 
In the control experiments, ASRE-(U) has limited effects on the 
DMPK mRNA level in myocytes derived from normal fibroblasts 
through the transfection of MyoD followed by differentiation 
(Supplementary Figure S2).
We also used an in situ hybridization with a Cy5-labeled 
(CAG)10 probe to detect (CUG)n repeats in DM1 cells. As 
expected, the DM1 cells had an average of 8–9 nuclear foci con-
taining (CUG)n accumulation, whereas the normal cells had no 
detectable nuclear accumulation of (CUG)n (Figure 4a). When 
transfected with ASRE-(U), the number of nuclear foci in DM1 
cells was significantly decreased, whereas the mutated ASRE-(U) 
had no detectable effect (Figure 4a). Importantly, the numbers 
of cells with at least five nuclear foci were decreased from 66 to 
20% by ASRE-(U) treatment, and the majority of ASRE-treated 
cells had 3–4 foci (Figure 4b). In comparison, the expression of 
mutated ASRE-(U) or ASRE-(G) had no obvious effect on the 
Figure 1 Generation of PUF domains to recognize CUG repeats. (a) Diagram of PUF domain and their target 8-nt in CUG repeats. The (CUG)n 
repeats can be recognized as 8-nt by three different frames (different shades of gray coded for clarity), thus three possible PUF domains (named by 
the first base of their targets) can be generated to recognize three cognate targets. (b) The long (CUG)n repeats in myotonic dystrophy type 1 patients 
forms a double-stranded hairpin structure. The target 8-nt sequences for three PUF domains were shown in gray in the context of the RNA hairpin. (c) 
Measurement of RNA–protein interactions using yeast three-hybrid system. The binding of wild-type (WT) PUF-cognate RNA was used as a control. 
We tested each PUF with a short repeat of (CUG)5, a long repeat of (CUG)20, and a control repeat (CAG)20. (d) Electrophoretic mobility shift assay 
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numbers of (CUG)n containing nuclear foci (Figure 4a,b), con-
sistent with the finding that PUF(G) did not bind long repeat of 
(CUG)n (Figure 1c,d). The reduction of nuclear foci by ASRE-(U) 
was statistically significant (P = 2.5 × 10−15, t-test), suggesting that 
this ASRE can indeed reduce the accumulation of toxic RNAs as 
designed. A small but statistically significant reduction of nuclear 
foci was also observed in another DM1 cell line (GM04033; 
Supplementary Figure S3), which further supported the effec-
tiveness of ASRE as a general therapeutic reagent.
In addition, we also found that the expression of ASRE-(U) 
reduced the nuclear sequestration of MBNL1, as judged by immu-
nofluorescence using MBNL1 antibody. The MBNL1 in DM1 cells 
usually are localized as nuclear foci with (CUG)n repeats, and we 
found that ASRE-(U), but not ASRE-(G) or mutated ASRE-(U), 
reduced such localization and made MBNL1 defused inside cells 
(Figure 4d).
ASREs reversed abnormal regulation of alternative 
splicing in human DM1 cells
The toxic RNA repeats in DM1 can affect multiple splicing factors 
(e.g., MBNL1 and CUGBP) that subsequently cause deregulated 
splicing in multiple mRNAs, and such splicing shift contributes 
to most of DM1 phenotypes. Given that we have succeeded in 
partially degrading mutant DMPK mRNAs and reducing the 
number of nuclear foci, we examined the effect on the deregulated 
splicing of several genes that are responsible for many DM1 phe-
notypes, including insulin resistance,13 T-tubule alterations and 
muscle weakness15, and cardiac conduction defects.9,14
The insulin receptor can produce two isoforms through alter-
native splicing of exon 11 of α-subunit: IR-A (lacking exon 11) 
and IR-B (including exon 11). In DM1 cells, exon 11 of IR gene 
is largely skipped to generate isoform A that has a lower signaling 
capacity40 (Figure 5a, first two lanes). The expression of ASRE-(U) 
partially reversed such splicing defect by promoting the inclusion 
of exon 11 (Figure 5a). Similar effect of splicing restoration was 
also observed in a DM1 cell line derived from another patient 
(GM04033), suggesting that the ASRE has the potential to reverse 
the phenotypes caused by IR missplicing in different DM1 patients 
(Supplementary Figure S4a).
BIN1 is another gene that is misregulated in DM1. This gene 
is involved in the formation of T tubule in skeletal muscles, and 
its exon 11 encodes a phosphoinositide-binding domain and is 
mostly skipped in DM1.15 The missplicing of BIN1 caused the 
expression of an inactive BIN1 that lacks phosphatidylinositol 
5-phosphate binding and membrane-tubulating activities.15 The 
expression of ASRE-(U) restored the normal splicing pattern of 
BIN1 to produce BIN1 mRNA that contains exon 11 (Figure 5b). 
Interestingly, the mutated ASRE-(U) with an inactive PIN also 
reversed the splicing of BIN1, suggesting that the binding of 
artificial protein alone may disperse the MBNL proteins from 
nuclear foci to restore splicing. A similar effect was also observed 
in another DM1 cell lines with both WT and mutated ASRE-(U) 
(Supplementary Figure S4b).
As the cardiac isoform of TNT, cTNT, is the subunit of tropo-
nin complex with an important role in the regulation of muscle 
contraction. There are two major cTNT isforms generated by 
alternative splicing of exon 5 with different calcium sensitivity to 
the myofilament, and this alternative splicing event is develop-
mentally regulated.9,14 Exon 5 of cTNT is included in the mature 
mRNAs during early development of the heart and skeletal mus-
cle, but in adult heart, the exon is skipped. In DM1 patients, cTNT 
is misspliced to cause inappropriate inclusion of exon 5 in adult 
cardiac muscle. As expected, exon 5 was predominately excluded 
in normal cells but was mainly included in DM1 cells (Figure 5c). 
The expression of ASRE-(U) induced the skipping of exon 5 in 
mature cTNT mRNAs to partially restore normal splicing pattern. 
The mutated ASRE-(U) again has a residual activity in changing 
splicing, whereas the ASRE-(G) had no effect (Figure 5c). A simi-
lar effect was observed in GM04033 with both WT and mutated 
ASRE-(U) (Supplementary Figure S4c).
The Nfix gene encodes NF-I/X CAAT box-binding transcrip-
tion factor that functions as a switch in the development of skel-
etal muscle from embryonic to fetal stage. A recent study showed 
that the Nfix exon 9 was aberrantly included in mouse models of 
DM.12 Again we found that the expression of ASRE-(U) caused 
a significant decrease of exon 9 inclusion to reverse the DM1-
specific splicing (Figure 5d). A similar effect was also observed in 
GM04033 with ASRE-(U) (Supplementary Figure S4d).
SET and MYND domain containing protein 1 (SMYD1) 
is another DM1-affected gene that is specifically expressed in 
Figure 2 Artificial site-specific RNA endonucleases (ASREs) degrade 
CUG repeats in COS7 cells. (a) Diagram of the DT480 and DT12 
minigene constructs. The minigenes contain exons 11–15 of human 
dystrophia myotonica-protein kinase gene and interrupted CTG repeats 
(DT480, 480 CTG repeats; DT 12, 12 CTG repeats) expressed by a 
cytomegalovirus (CMV) promoter. Primer pairs for reverse transcrip-
tase–polymerase chain reaction (RT-PCR) are indicated by arrows. (b) 
The minigene construct and ASRE expression plasmid were cotrans-
fected into COS7 cells, and the RNA levels were measured with real-
time RT-PCR at 48 hours after transfection. The messenger RNA levels of 
GAPDH were also measured as internal controls, and the P values were 
calculated according to t-test (only significant difference was shown). 
The expressions of ASREs were detected using western blot and showed 
below each sample.
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skeletal and cardiac muscles. SMYD1 functions as a histone meth-
yltransferase to regulate gene transcription and is essential for 
myogenic differentiation.41 Exon 5 of Smyd1 mRNAs is aberrantly 
included in human DM1 sample and HSALR and Mbnl1ΔE3/ΔE3 mice 
model.12 ASRE-(U) expression decreased the inclusion of exon 5 
in mature mRNAs, and a partial restoration was again obtained 
with the mutated ASRE-(U) (Figure 5e).
The last gene we tested, SERCA1, functions as a regulator of 
intracellular Ca2+ homeostasis in skeletal muscle cells. This gene 
has two major splice variants (SERCA1a and SERCA1b) resulting 
from the alternative splicing of its exon 22.42,43 Exon 22 is included 
in adult muscle but excluded in skeletal muscle of DM1 patients, 
which is regulated by MBNL1.16,17 The expression of ASRE-(U), and 
to a lesser extent mutated ASRE-(U), induced the inclusion of exon 
22 in mature SERCA1 mRNAs to partially restore normal splicing 
pattern (Figure 5f), whereas the ASRE-(G) has no obvious effect on 
its splicing. As controls, we also examined the effect of ASREs on 
the WT cells in a parallel experiment and found that the splicing of 
the above genes were unaffected (Supplementary Figure S5).
DISCUSSION
Here, we reported the first attempt to develop a treatment of DM1 
with an artificial enzyme. This new gene therapy approach used a 
custom-designed RNA endonuclease to specifically bind and cleave 
(CUG)n repeats. Compared with conventional gene therapy that 
used MBNL1 to restore normal adult-splicing patterns and reduce 
muscle myotonia,19 our method directly targets the toxic RNA 
repeats. Because multiple muscleblind proteins are sequestered and 
other RNA-binding factors (e.g., CUGBP1 and staufen1) are also 
affected in DM1 patients, conventional gene therapy approach can-
not restore the normal level of all the factors affected. On the other 
hand, this protein-based approach will take advantage of available 
gene therapy tools (e.g., AAV vectors) to achieve efficient delivery 
in muscle and heart, thus circumventing the difficulties of in vivo 
delivery associated with antisense oligonucleotide–based methods.
Using cultured cells derived from DM1 patients, we showed 
that the designer RNA endonucleases decreased the level of toxic 
RNAs (Figure 3), rescued the number of nuclear foci (Figure 4), 
and restored the normal splicing patterns of multiple pre-mRNAs 
affected in DM1 (Figure 5). Interestingly, we have found that the 
abnormal splicing of some genes (such as BIN1, SMYD1, and 
SERCA1) can be partially restored by the mutated ASRE-(U) with 
an inactive PIN domain, whereas the others can only be reversed 
by active ASRE-(U). Such results could be caused by two possible 
reasons. First, it was reported that the D1353A mutation of PIN 
did not completely abolish its RNA endonuclease activity inside 
cells, although this RNase activity is undetectable in vitro with 
purified recombinant PIN.29,37 Second, the mutated ASRE-(U) 
Figure 3 Artificial site-specific RNA endonuclease (ASRE) specifically reduces dystrophia myotonica-protein kinase (DMPK) messenger RNA 
(mRNA) levels with CUG repeats in myotonic dystrophy type 1 (DM1) cells. (a) Schematic representation of ASRE treatment in DM1 myocytes 
derived from patient fibroblasts. The DM1 patient fibroblasts (GM04602) were stably transfected with human MyoD and further cultured for 7 days 
to convert them into myoblasts. The resulting cells were stably transfected with ASREs, after incubation for 10 days, the myoblasts were induced 
into myocytes with differentiation medium, and the cells were harvested in another 10 days for further analyses. (b) The protein levels of ASREs were 
examined by western blot. The differentiation levels of myoblasts were determined by the expression of Desmin. As an internal control, the α-tubulin 
was detected. (c) The (CUG)n repeats in differentiated GM04602 cells were assayed by fluorescence in situ hybridization (FISH) using (CAG)10 probes 
(red), and the localization of ASRE was detected with immunofluorescence (green). As a negative control, the cells were transfected with expression 
vector only. The nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Scale bar = 10 µm. (d) For the same cells described above, the mRNA 
levels of DMPK were examined with real-time reverse transcriptase–polymerase chain reaction. P values were calculated according to t-test (only 
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could also function as a competitor to disperse the sequestered 
MBNL proteins from nuclear foci and thus caused splicing res-
toration. Consistently, MBNL1 was shown to be the primary 
regulator of alternative splicing of BIN1,15 SMYD1,12 and SERCA117 
in DM1 patients. For the genes whose splicing was reversed by 
WT ASRE-(U) but not by inactive ASRE-(U), it is possible that 
their splicing is mainly regulated by splicing factors other than 
MBNL in DM1 cells. For example, the splicing of cTNT and IR 
was mainly controlled by CUGBP9,13 but also can be regulated by 
MBNL in an opposite way.14 Therefore, dispersing of MBNL pro-
teins by inactive ASRE-(U) had less effect on their splicing, and an 
active ASRE-(U) was required for splicing restoration.
We found that the degradation of (CUG)n repeat is the most 
efficient for long repeats (Figure 2b), presumably because the 
long repeats have more binding sites of the enzyme. The bind-
ing between PUFs and RNA was also affected by RNA structure. 
We speculate that PUF(G) preferably bound its targets in sin-
gle-stranded RNA rather than in the hairpin structure of a long 
repeat, whereas PUF(U) and PUF(C) recognized 8-nt binding site 
in both structures (Figure 1c). Since (CUG)12 is long enough to 
form a hairpin structure that is similar to (CUG)20 or (CUG)480, 
ASRE(G) was found to slightly degrade (CUG)480 but not (CUG)12 
(Figure 2b). This explanation assumes that (CUG)n repeat adopts 
a hairpin structure inside cells similar to its in vitro structure.34,35,44 
Since there is no direct evidence of (CUG)n structure inside cells, 
other explanations are possible.
Compared with native RNA endonucleases (e.g., RNase A 
or H), we found that ASREs have a fairly slow catalytic rate with 
kcat ranging from 10 to 50 per minute.
29 However, the catalytic 
efficiency (kcat/KM) of ASREs is reasonably high for typical RNA 
endonucleases (kcat/KM >10
7 (mol/l)−1 minute−1) due to the high 
binding affinity between the enzyme and its substrate (i.e., a low 
KM). This finding suggested that the catalytic efficiency of ASREs 
are mainly provided by the tight binding between the enzyme and 
its cognate RNA substrate, consistent with our finding that the 
short RNA repeats with less binding sites are poor substrates for 
ASRE-catalyzed degradation (Figure 2b). Such catalytic property 
provided a favorable feature for the application of ASRE as DM1 
treatment, as the WT alleles of DMPK in DM1 patients are much 
less efficiently being cleaved by ASRE. Consistently, we found that 
ASRE-(U) can only decrease the level of DMPK mRNAs by ~40% 
(Figure 3d) even after a treatment for 10 days, suggesting that 
ASRE indeed has low activity toward WT DMPK mRNAs.
As the proof of concept for a new therapeutic approach, there 
are remaining questions need to be addressed in the future. For 
example, the ASRE-(U) recognize its targets by 8-nt, suggesting 
that there are possible off-target effect in other genes. However, 
the low catalytic rate of ASRE limited its off-target effect toward 
low-repetitive substrate, which is supported by the finding that the 
mRNA levels of the two genes with low number of CUG repeats 
(CASK: 16 repeats, MAP3K4: 11 repeats) are barely affected by 
ASRE-(U) (Supplementary Figure S6). Nevertheless, a thorough 
assessment of the levels for all other RNAs by mRNA-seq is needed 
in DM1 animal model treated with ASREs. Our study paves the 
way for the future test of in vivo efficacy of ASREs in DM1 ani-
mals, which can be carried out with standard gene delivery vec-
tors for muscle and heart (e.g., AAV). Because the applications 
of AAV vectors have been extensively tested for muscular dystro-
phy and neurodegenerative diseases,45,46 our approach can benefit 
from these studies in the next stage of therapy development.
Figure 4 Cellular effects of artificial site-specific RNA endonucleases 
(ASREs) in myotonic dystrophy type 1 patient cells. (a) GM04602 
cells and normal human fibroblast cells were induced into myocytes, 
and then examined by by fluorescence in situ hybridization (FISH) using 
(CAG)10 probes. GM04602 cells were transfected with different ASREs or 
vector control. 4′,6-Diamidino-2-phenylindole (DAPI) was used to stain 
the nuclei. Scale bar = 5 µm. (b) The differentiated GM04602 cells trans-
fected with vector or different ASREs were selected from random fields 
and counted for the number of nuclear foci. The percentages of cells 
with different number of nuclear foci were represented as a histogram. 
From left to right, n = 133, 126, 81, and 67. (c) The number of nuclear 
foci of differentiated GM04602 cells transfected with vector or ASRE-(U) 
were counted and represented as box plot. The average numbers were 
indicated by diamonds, and a significant decrease (P = 2. 5 × 10−15, t-test) 
of foci number were observed in ASRE-(U) treated cells. (d) For the same 
cells described above, the localization of MBNL1 proteins was detected 
with immunofluorescence (green). The (CUG)n repeats and the nuclear 
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MATERIALS AND METHODS
Yeast three-hybrid assays. Different PUF domains were cloned into the 
pACT2 plasmid and modified for distinct targets using QuikChange kits 
(Agilent Technologies, La Jolla, CA ). The target sequences were inserted 
into pIIIA-MS2-2 vector using SmaI and SphI.32 Yeast three-hybrid assays 
were performed in YBZ-1 strain. The activity of β-galactosidase was mea-
sured using LacZ reporter assay as described previously.32 Briefly, the yeast 
colonies were randomly chosen and inoculated into individual wells of a 
96-well plate and incubated overnight at 30 °C with shaking to reach mid-
log phase. The reaction was set up by transferring 20 µl of yeast culture 
into a new plate containing 180 µl of Z-buffer.32 After incubation at 37 °C 
for 2 hours, 80 µl of 1 mol/l carbonate solution was added into each well 
to stop the reaction. The A405 was measured using a spectrophotometer to 
quantify the yellow-colored product (nitrophenol). The β-galactosidase 
units were calculated according to the difference of A405 between the sam-
ples and the background calibrated by culture densities.
Cell culture and transfection. COS7 cells were grown in Dulbecco’s 
modified Eagle’s medium (Gibco, Grand Island, NY) supplemented with 
10% fetal bovine serum. These cells were cotransfected with 0.5 µg of 
DT12 or DT480 reporters and 1 µg of ASREs expression plasmid using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Forty-eight hours after 
transfection, the cells were collected for purification of total proteins and 
RNA. The ASRE levels were determined by western blot with anti-FLAG 
Figure 5 The reverse of aberrant alternative splicing by artificial site-specific RNA endonucleases (ASREs) expression in myotonic dystrophy 
type 1 (DM1) cells. Semi-quantitative reverse transcriptase–polymerase chain reaction was used to detect different alternative splicing isoforms for 
(a) insulin receptor (a), (b) bridging integrator-1, (c) cTNT, (d) Nfix, (e) SMYD 1, and (f) SERCA1 in differentiated DM1 cells (GM04602). We used 
differentiated normal human fibroblast and DM1 cells transfected with vector only as controls. At least two independent experiments were carried 
out, with the means and SD of the percent-splice-in (psi) shown below a representative gel. In all panels, the P values were calculated by t-test com-
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M2 (Sigma, St Louis, MO), and the levels of mRNA were measured by 
real-time RT-PCR.
DM1 fibroblasts (GM04602 or GM04033) were purchased from 
Coriell Cell Repositories (Camden, NJ). The fibroblasts were maintained 
in minimal essential medium (Gibco) supplemented with 15% fetal 
bovine serum and nonessential amino acids at 37 °C under 5% CO2 as 
recommended by Coriell.
Conversion from fibroblasts to skeletal muscle. MyoD cDNA was cloned 
into lentiviral vector pCDH-CMV-MCS-EF1-Puro (System Biosciences, 
Mountain View, CA). The lentivirus production was carried out according 
to the manufacturer’s instructions. The supernatants containing the viral 
vector were used to infect DM1 fibroblasts. After 24 hours of incubation, 
the infected cells were selected with normal culture media containing 5 
µg/ml puromycin for 7 days. The MyoD-transduced fibroblasts (myo-
blasts) were reinfected with ASREs lentiviral supernatant following the 
manufacturer’s protocols. Infected fibroblasts were incubated in differen-
tiation medium (Dulbecco’s modified Eagle’s medium supplemented with 
1% heat-inactivated horse serum, 10 µg/ml insulin, and 10 µg/ml transfer-
rin) for 10 days to differentiate to myocytes. The expression of ASREs and 
desmin were determined by western blot.
RNA extraction and RT-PCR. Total RNA was extracted from cultured 
cells using TRIzol (Invitrogen) according to the manufacturer’s proto-
col. The RNA was treated with RNase-free DNase I (Promega, Madison, 
WI) at 37 °C for 1 hour and then incubated at 70 °C for 15 minutes to 
inactivate DNase. First-strand cDNA was synthesized using high capac-
ity cDNA reverse transcription kit (Applied Biosystems, Foster City, 
CA) with random primers. DMPK and GAPDH mRNA levels were 
determined by real-time PCR using Applied Biosystem 7500 fast Real-
Time PCR System and Thermo Scientific Maxima SYBR Green/ROX 
qPCR Master Mix. For the analysis of alternative splicing of IR, BIN1, 
cTNT, Nfix, SMYD1, and SERCA1, 2 µl cDNA was used as the template 
for semi-quantitative PCR as described previously (primers are shown 
in Supplementary Table S1).47
Fluorescence in situ hybridization and immunofluorescence. 
Fluorescence in situ hybridization was performed to detect the (CUG)n 
repeats in DM1 myocytes using Cy5-labeled (CAG)10 probe. The cells were 
inoculated and cultured in cover slide and were washed with phosphate-
buffered saline (PBS) and then with cytoskeleton buffer (300 mmol/l 
sucrose, 100 mmol/l NaCl, 3 mmol/l MgCl2, 1.2 mmol/l phenylmeth-
ylsulfonyl fluoride, and 10 mmol/l piperazine-N,N'-bis(ethanesulfonic 
acid), pH 6.8) before the experiments. The slides were incubated for 5 
minutes in cytoskeleton buffer with 0.5% Triton X-100 at 4 °C, fixed in 
4% paraformaldehyde in PBS for 15 minutes, and then rinsed in 70% 
ethanol at 4 °C. The cells were dehydrated through a series of ethanol 
incubation for 3 minutes each in 70, 80, 95, and 100% ethanol. The cells 
were incubated with probe mixture (50% formamide, 2× saline sodium 
citrate (SSC), 0.2% bovine serum albumin, 10% dextran sulfate, 2 mmol/l 
vanadyl sulfate, 0.5 mg/ml yeast tRNA, and 50 ng probe) at 37 °C for 3 
hours in a humidified chamber. The slides were washed three times with 
2×SSC/50% formamide for 10 minutes at room temperature and once 
at 37 °C followed by three times wash with 2×SSC at room temperature. 
The slides were transferred to a jar with 4×SSC/0.1% Tween. For immu-
nofluorescence after fluorescence in situ hybridization, the slides were 
then incubated with 3% bovine serum albumin/PBS 30 minutes at 37 °C, 
incubated with primary anti-MBNL1 antibody 3A4 (1:1,000, Santa Cruz 
Biotechnology, Dallas, TX) in 3% bovine serum albumin/PBS at 37 °C 
for 90 minutes, washed three times with 4×SSC/0.1% Tween, and incu-
bated with the secondary antibody (Alexa Fluor 488-labeled goat anti-
mouse IgG, Invitrogen) in 3% bovine serum albumin/PBS for 30 minutes. 
Following the incubation, cells were washed three times with 4×SSC/0.1% 
Tween. The slides were mounted with mounting media with 4′,6-diamid-
ino-2-phenylindole (Vector laboratories, Burlingame, CA).
SUPPLEMENTARY MATERIAL
Figure S1. Design of ASREs.
Figure S2. The expression of ASREs have no effect on DMPK mRNA in 
differentiated normal human fibroblasts.
Figure S3. Cellular effects of ASREs in GM04033 cells.
Figure S4. The reverse of aberrant alternative splicing by ASREs ex-
pression in GM04033 cells.
Figure S5. The expression of ASREs have no effect on alternative splic-
ing in normal cells.
Figure S6. Effect of ASRE-(U) on other mRNA containing short CUG 
repeat.
Table S1. Primers used in detection of different mRNA isoforms.
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